{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:13:58Z","timestamp":1766412838118,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770764"],"award-info":[{"award-number":["81770764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04491-3","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:10:50Z","timestamp":1766412650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cotrimoxazole for infection prevention in glomerulonephritis treated with rituximab: a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Ye","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anlan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengpei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"9473","key":"4491_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/S0140-6736(05)66583-X","volume":"365","author":"SJ Chadban","year":"2005","unstructured":"Chadban SJ, Atkins RC. Glomerulonephritis. Lancet. 2005;365(9473):1797\u2013806.","journal-title":"Lancet"},{"issue":"7","key":"4491_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"HJ Anders","year":"2023","unstructured":"Anders HJ, Kitching AR, Leung N, Romagnani P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat Rev Immunol. 2023;23(7):453\u201371.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"4491_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ndt\/gfu294","volume":"30","author":"S Titze","year":"2015","unstructured":"Titze S, Schmid M, Kottgen A, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort[J]. Nephrol Dial Transplant. 2015;30(3):441\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"4491_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.kint.2016.04.026","volume":"90","author":"JB Wetmore","year":"2016","unstructured":"Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. Kidney Int. 2016;90(4):853\u201360.","journal-title":"Kidney Int"},{"issue":"6","key":"4491_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67(6):1577\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"6483","key":"4491_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Rouge","year":"2020","unstructured":"Rouge L, Chiang N, Steffek M, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367(6483):1224\u201330.","journal-title":"Science"},{"key":"4491_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110317","volume":"120","author":"MR Hua","year":"2023","unstructured":"Hua MR, Zhao YL, Yang JZ, Zou L, Zhao YY, Li X. Membranous nephropathy: mechanistic insights and therapeutic perspectives. Int Immunopharmacol. 2023;120:110317.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4491_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial[J]. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4491_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4491_CR10","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1002\/art.27541","volume":"62","author":"B Terrier","year":"2010","unstructured":"Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458\u201366.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4491_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102505","volume":"19","author":"C Thery-Casari","year":"2020","unstructured":"Thery-Casari C, Euvrard R, Mainbourg S, et al. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis. Autoimmun Rev. 2020;19(5):102505.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"4491_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184\u201391.","journal-title":"JAMA Neurol"},{"issue":"3","key":"4491_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/eci.12410","volume":"45","author":"A Kronbichler","year":"2015","unstructured":"Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346\u201368.","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"4491_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, Kerschbaum J, Gopaluni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4491_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler B, Riedl R, Gauckler P, et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann Rheum Dis. 2023;82(5):681\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4491_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2021;112(1):90\u20132.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"issue":"9237","key":"4491_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"issue":"9","key":"4491_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2217\/fon.15.57","volume":"11","author":"P Feugier","year":"2015","unstructured":"Feugier P. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin\u2019s lymphomas. Future Oncol. 2015;11(9):1327\u201342.","journal-title":"Future Oncol"},{"key":"4491_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245","volume":"8","author":"M Marshall","year":"2017","unstructured":"Marshall M, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245.","journal-title":"Front Immunol"},{"issue":"12","key":"4491_CR20","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2215\/CJN.05900420","volume":"15","author":"DA Glenn","year":"2020","unstructured":"Glenn DA, Henderson CD, O\u2019Shaughnessy M, et al. Infection-related acute care events among patients with glomerular disease. Clin J Am Soc Nephrol. 2020;15(12):1749\u201361.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement_2","key":"4491_CR21","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1093\/ndt\/gfad080","volume":"38","author":"M Windpessl","year":"2023","unstructured":"Windpessl M, Kostopoulou M, Conway R, et al. Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis. Nephrol Dial Transplant. 2023;38(Supplement_2):ii40\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"4491_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrmicro1621","volume":"5","author":"CJ Thomas","year":"2007","unstructured":"Thomas CJ, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298\u2013308.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4491_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1378\/chest.12-0477","volume":"144","author":"I Martin-Garrido","year":"2013","unstructured":"Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013;144(1):258\u201365.","journal-title":"Chest"},{"issue":"3","key":"4491_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/art.24283","volume":"61","author":"Y Komano","year":"2009","unstructured":"Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61(3):305\u201312.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4491_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15257","volume":"35","author":"H Faraji","year":"2022","unstructured":"Faraji H, Daneshpazhooh M, Ehsani AH. Evaluating the risk\u2010to\u2010benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients. Dermatol Ther. 2022;35(2):e15257.","journal-title":"Dermatol Ther"},{"issue":"1","key":"4491_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/myc.13184","volume":"64","author":"JY Lee","year":"2021","unstructured":"Lee JY, Kang M, Suh KJ, et al. Pneumocystis jirovecii pneumonia in diffuse large B-cell lymphoma treated with R-CHOP. Mycoses. 2021;64(1):60\u20135.","journal-title":"Mycoses"},{"issue":"1","key":"4491_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01503-z","volume":"24","author":"P Munthananuchat","year":"2024","unstructured":"Munthananuchat P, Ngamjanyaporn P, Pisitkun P, Rotjanapan P. The role of trimethoprim\/sulfamethoxazole in preventing opportunistic infections in systemic lupus erythematosus patients receiving low-level immunosuppressive treatment: an open-label, randomized, controlled trial. Clin Exp Med. 2024;24(1):241.","journal-title":"Clin Exp Med"},{"issue":"6","key":"4491_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0961203321995238","volume":"30","author":"SA Ganu","year":"2021","unstructured":"Ganu SA, Mathew AJ, Nadaraj A, Jeyaseelan L, Danda D. Cotrimoxazole prophylaxis prevents major infective episodes in patients with systemic lupus erythematosus on immunosuppressants: a non-concurrent cohort study. Lupus. 2021;30(6):893\u2013900.","journal-title":"Lupus"},{"issue":"19","key":"4491_CR29","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888\u201398.","journal-title":"JAMA"},{"issue":"1","key":"4491_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1206-8","volume":"19","author":"M Utsunomiya","year":"2017","unstructured":"Utsunomiya M, Dobashi H, Odani T. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther. 2017;19(1):7.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4491_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park JW, Curtis JR, Jun KI, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab[J]. Chest. 2022;161(5):1201\u201310.","journal-title":"Chest"},{"issue":"5","key":"4491_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/eci.09.31","volume":"5","author":"PJ Bugelski","year":"2009","unstructured":"Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499\u2013521.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"4491_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3899\/jrheum.2023-0623","volume":"51","author":"YS Sun","year":"2024","unstructured":"Sun YS, Huang DF, Chen WS, et al. Risk factors and incidence of serious infections in patients with systemic lupus erythematosus undergoing rituximab therapy. J Rheumatol. 2024;51(2):160\u20137.","journal-title":"J Rheumatol"},{"issue":"3","key":"4491_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04491-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04491-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:10:51Z","timestamp":1766412651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-025-04491-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4491"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04491-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the First Affiliated Hospital of the Air Force Military Medical University approved the study protocol on 7 July 2022 (Ethics Approval No.: KY20222140-F-1). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"688"}}